Navamedic signs distribution agreement
(Thomson Reuters ONE) -
Navamedic has signed an exclusive distribution agreement with the German
pharmaceutical company Pohl-Boskamp for its new head lice remedy NYDA.
(Oslo, 6 December 2010) The agreement with Pohl-Boskamp opens another market for
Navamedic's fully owned subsidiary Vitaflo Scandinavia. Through the agreement
Vitaflo Scandinavia will gain the exclusive right to distribute the new and
unique head lice remedy NYDA in Norway, Sweden and Denmark. The market for head
lice in these countries is estimated to be worth approximately SEK 18 million
per year.
"We welcome the distribution agreement and register a growth in the demand for
these types of products. NYDA is recommended by the Swedish pharmaceutical
authority (Legemiddelverket) which we believe is an important reassurance for
the consumers," said Olof Milveden, CEO of Navamedic.
NYDA is a completely new head lice remedy. The active ingredients in the product
penetrate the airways of both the lice and its eggs and cause suffocation. If
used as prescribed, users will get rid of all lice with one treatment. NYDA is a
mild product and is suitable for children from the age of two.
Pohl-Boskamp is a German pharmaceutical company with a long history and track
record. It is known for its dedication to health promoting activities and
quality in manufacturing pharmaceutical products and medical equipment since
1835. Pohl-Boskamp's products are sold in 45 countries.
This agreement is one in a series of recent deals for Navamedic and illustrates
the company's growth strategy. Earlier this year, Navamedic signed an exclusive
agreement with the Norwegian company Smartfish for the distribution of its
products within Medical Nutrition in Sweden, Denmark and Finland. Navamedic has
also signed an exclusive agreement with Aspen Healthcare giving Navamedic the
right to market Aspens products in Norway and the Benelux countries. Aspen is
one o the world's largest producer of generic products.
For further information:
Olof Milveden, CEO, Navamedic ASA
Telephone +46 31 335 11 90 or mobile + 46 733 463736
Håkan Josephsson, CEO, Vitaflo Scandinavia AB
Telephone +46 31 335 11 93 or mobile: +46 70 674 25 33
-------------------------------------------------------------------------------
Navamedic ASA is a fast-growing speciality pharma company with high growth
ambitions. Navamedic markets a portfolio of more than 45 products from more than
20 producers in Sweden, Denmark, Finland, Norway and Holland.
The company is constantly seeking products to complement the existing portfolio
within selected knowledge areas.
Navamedic ASA has been listed on the Oslo Børs (Oslo stock exchange) since 31
March, 2006.
The group includes Navamedic ASA and the subsidiaryVitaflo Scandinavia AB
(Vitaflo). The group's head office is at Lysaker outside Oslo, Norway.
Vitaflo was established in 1999 and became part of the Navamedic group in
October 2007. Vitaflo is a speciality pharma company with focus on acquiring
and/or in-licensing of products within selected knowledge areas. Vitaflo markets
its products directly in Sweden, Denmark, Norway, Finland and Holland, and
exports products outside these markets. Vitaflo currently markets more than 40
products and has several products under registration. The product portfolio
consists of licensed products, original pharmaceuticals and generic products.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Navamedic ASA via Thomson Reuters ONE
[HUG#1468812]
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2010 - 09:01 Uhr
Sprache: Deutsch
News-ID 49421
Anzahl Zeichen: 4447
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 350 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Navamedic signs distribution agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
